Systemic T cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Domenis, Rossana ^a   Cesselli, Daniela ^a   Toffoletto, Barbara ^a   Bourkoula, Evgenia ^a,c   Caponnetto, Federica ^a   Manini, Ivana ^a   Beltrami, Antonio Paolo ^a   Ius, Tamara ^b   Skrap, Miran ^b   Di Loreto, Carla ^a   Gri, Giorgia ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c Department of Molecular Biology GENEKOR   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD69 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL MATURATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; EFFECTOR CELL; EXOSOME; GLIOMA STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MONOCYTE; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; MYELOID-DERIVED SUPPRESSOR CELL; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR GROWTH; BLOOD; BRAIN TUMOR; CANCER STEM CELL; CELL CULTURE; CELL PROLIFERATION; COCULTURE; FLOW CYTOMETRY; GLIOBLASTOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

BRAIN NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; EXOSOMES; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; MONOCYTES; NEOPLASTIC STEM CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 85010469830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169932     Document Type: Article

References (53)

1. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999; 100:216-32. PMID: 10695732
2. Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am. 2010; 21: 31-42. doi: 10.1016/j.nec.2009.08.005 PMID: 19944964
3. Gustafson MP, Lin Y, New KC, Bulur PA, O'Neill BP, Gastineau DA, et al. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010; 12: 631-44. doi: 10.1093/neuonc/noq001 PMID: 20179016
4. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006; 66: 3294-302. doi: 10.1158/0008-5472.CAN-05-3773 PMID: 16540683
5. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010; 12: 351-65. doi: 10.1093/neuonc/nop023 PMID: 20308313
6. Brooks WH, Latta RB, Mahaley MS, Roszman TL, Dudka L, Skaggs C. Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status. J Neurosurg. 1981; 54: 331-7. doi: 10.3171/jns.1981.54.3.0331 PMID: 7007589
7. Parney IF. Basic concepts in glioma immunology. Adv Exp Med Biol. 2012; 746:42-52. doi: 10.1007/978-1-4614-3146-6-4 PMID: 22639158
8. Rolle CE, Sengupta S, Lesniak MS. Mechanisms of immune evasion by gliomas. Adv Exp Med Biol. 2012; 746: 53-76. doi: 10.1007/978-1-4614-3146-6-5 PMID: 22639159
9. Zou JP, Morford LA, Chougnet C, Dix AR, Brooks AG, Torres N, et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol. 1999; 162: 4882-92. PMID: 10202033
10. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CLL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015; 29:1203-17. doi: 10.1101/gad.261982.115 PMID: 26109046
11. Hatiboglu MA, Wei J, Wu ASG, Heimberger AB. Immune therapeutic targeting of glioma cancer stem cells. Target Oncol. 2010; 5: 217-27. doi: 10.1007/s11523-010-0151-8 PMID: 20737294
12. Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010; 16:461-73. doi: 10.1158/1078-0432.CCR-09-1983 PMID: 20068105
13. Wu A, Wei J, Kong L-Y, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12:1113-25. doi: 10.1093/neuonc/noq082 PMID: 20667896
14. Bullerdiek J, Flor I. Exosome-delivered microRNAs of "chromosome 19 microRNAcluster" as immunomodulators in pregnancy and tumorigenesis. Mol Cytogenet. BioMed Central; 2012; 5: 27.
15. Lo Cicero A, Stahl PD, Raposo G. Extracellular vesicles shuffling intercellular messages: for good or for bad. Curr Opin Cell Biol. 2015; 35: 69-77. doi: 10.1016/j.ceb.2015.04.013 PMID: 26001269
16. Chistiakov DA, Chekhonin VP. Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. Tumour Biol. 2014; 35: 8425-38. doi: 10.1007/s13277-014-2262-9 PMID: 24969563
17. Basso M, Bonetto V. Extracellular Vesicles and a Novel Form of Communication in the Brain. Front Neurosci. 2016; 10:127. doi: 10.3389/fnins.2016.00127 PMID: 27065789
18. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007; 67: 7458-66. doi: 10.1158/0008-5472.CAN-06-3456 PMID: 17671216
19. Filipazzi P, Bürdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol. 2012; 22: 342-9. doi: 10.1016/j.semcancer.2012.02.005 PMID: 22369922
20. Harshyne LA, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro Oncol. 2015
21. Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009; 23:1541-57. doi: 10.1096/fj.08-122184 PMID: 19109410
22. Liu Z-M, Wang Y-B, Yuan X-H. Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of CD8+T cells. Asian Pac J Cancer Prev. 2013; 14: 309-14. PMID: 23534743
23. Hellwinkel JE, Redzic JS, Harland TA, Gunaydin D, Anchordoquy TJ, Graner MW. Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol. 2016; 18: 497-506. doi: 10.1093/neuonc/nov170 PMID: 26385614
24. de Vrij J, Maas SLN, Kwappenberg KMC, Schnoor R, Kleijn A, Dekker L, et al. Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J cancer. 2015; 137:1630-42. doi: 10.1002/ijc.29521 PMID: 25802036
25. Redzic JS, Ung TH, Graner MW. Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharmgenomics Pers Med. 2014; 7: 65-77. doi: 10.2147/PGPM.S39768 PMID: 24634586
26. Bourkoula E, Mangoni D, Ius T, Pucer A, Isola M, Musiello D, et al. Glioma-associated stem cells: A novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas. Stem Cells. 2014; 32:1239-53. doi: 10.1002/stem.1605 PMID: 24375787
27. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009; 4: 568-80. doi: 10.1016/j.stem.2009.03.014 PMID: 19497285
28. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA. 2016; 113: E968-77. doi: 10.1073/pnas.1521230113 PMID: 26858453
29. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014; 1319: 47-65. doi: 10.1111/nyas.12469 PMID: 24965257
30. Trikha P, Carson WE. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta. 2014; 1846: 55-65. doi: 10.1016/j.bbcan.2014.04.003 PMID: 24727385
31. Peterson MF, Otoc N, Sethi JK, Gupta A, Antes TJ. Integrated systems for exosome investigation. Methods. 2015; 87: 31-45. doi: 10.1016/j.ymeth.2015.04.015 PMID: 25916618
32. Alvarez ML, Khosroheidari M, Kanchi Ravi R, DiStefano JK. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012; 82:1024-1032. doi: 10.1038/ki.2012.256 PMID: 22785172
33. Saenz-Cuesta M. Methods for extracellular vesicles isolation in a hospital setting. Front Immunol. 2015; 6.
34. Iorgulescu JB, Ivan ME, Safaee M, Parsa AT. The limited capacity of malignant glioma-derived exo-somes to suppress peripheral immune effectors. J Neuroimmunol. 2016; 290:103-8. doi: 10.1016/j.jneuroim.2015.11.025 PMID: 26711578
35. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived micro-vesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009; 183: 3720-30. doi: 10.4049/jimmunol.0900970 PMID: 19692638
36. Colombo M, Raposo G, Théry C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255-289. doi: 10.1146/annurev-cellbio-101512-122326 PMID: 25288114
37. Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep. 2016; 6: 20254. doi: 10.1038/srep20254 PMID: 26842680
38. Schreiner B, Wischhusen J, Mitsdoerffer M, Schneider D, Bornemann A, Melms A, et al. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia. 2003; 44: 296-301. doi: 10.1002/glia.10291 PMID: 14603470
39. Shibahara I, Saito R, Zhang R, Chonan M, Shoji T, Kanamori M, et al. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Mol Cancer. 2015; 14:41. doi: 10.1186/s12943-015-0307-3 PMID: 25744203
40. Zhu VF, Yang J, Lebrun DG, Li M. Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett. 2012; 316:139-50. doi: 10.1016/j.canlet.2011.11.001 PMID: 22075379
41. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, et al. IL-6 is required for glioma development in a mouse model. Oncogene. 2004; 23: 3308-16. doi: 10.1038/sj.onc.1207455 PMID: 15064729
42. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer. 2009; 125: 1054-1064. doi: 10.1002/ijc.24380 PMID: 19431143
43. Goswami S, Gupta A, Sharma SK. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem. 1998; 71:1837-45. PMID: 9798907
44. Tchirkov A, Rolhion C, Bertrand S, Doré JF, Dubost JJ, Verrelle P. IL-6 gene amplification and expression in human glioblastomas. Br J Cancer. 2001; 85: 518-22. doi: 10.1054/bjoc.2001.1942 PMID: 11506489
45. Carlsson A, Persson O, Ingvarsson J, Widegren B, Salford L, Borrebaeck CAK, et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl. 2010; 4: 591-602. doi: 10.1002/prca.200900173 PMID: 21137077
46. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 17: 3217-24. PMID: 9413151
47. Samaras V, Piperi C, Korkolopoulou P, Zisakis A, Levidou G, Themistocleous MS, et al. Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem. 2007; 304:343-351. doi: 10.1007/s11010-007-9517-3 PMID: 17551671
48. Taylor DD, Shah S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods. 2015; 87:3-10. doi: 10.1016/j.ymeth.2015.02.019 PMID: 25766927
49. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J Extracell Vesicles. 2014; 3.
50. Lobb RJ, Becker M, Wen SW, Wong CSF, Wiegmans AP, Leimgruber A, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell vesicles. 2015; 4: 27031. http://www.ncbi.nlm.nih.gov/pubmed/26194179 doi:10.3402/jev.v4.27031 PMID: 26194179
51. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10:1470-6. doi: 10.1038/ncb1800 PMID: 19011622
52. van der Vos KE, Abels ER, Zhang X, Lai C, Carrizosa E, Oakley D, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol. 2016; 18: 58-69. doi: 10.1093/neuonc/nov244 PMID: 26433199
53. Katakowski M, Chopp M. Exosomes as Tools to Suppress Primary Brain Tumor. Cell Mol Neurobiol. 2016; 36: 343-52. doi: 10.1007/s10571-015-0280-9 PMID: 26983831